written by reader Jeff Browns “Penny IPO`s”

by Zeflik | May 21, 2020 2:09 am

Does anyone could guess which `biotech/medical stock Jeff Brown[1] is promoting in the ”Penny IPO[2]`s” pitch? All of them have potential for at least 10x growth. Here is the link to the pitch https://secure.bonnerandpartners.com/?cid=MKT459805&eid=MKT463356&step=start&plcid=PLC069177&SNAID=SAC0010464081&email=jozef.szlufcik@gmail.com&encryptedSnaid=mtFugfkIjQZwvQduYvOPoJkMUqW8Rkx1t2V4kZtac6o%3D&emailjobid=4646829&emailname=20200520-TBE-F&assetId=AST136084&page=2[3]
Grtx,
Zeflik

Endnotes:
  1. Jeff Brown: https://www.stockgumshoe.com/tag/jeff-brown/
  2. IPO: https://www.stockgumshoe.com/tag/ipo/
  3. https://secure.bonnerandpartners.com/?cid=MKT459805&eid=MKT463356&step=start&plcid=PLC069177&SNAID=SAC0010464081&email=jozef.szlufcik@gmail.com&encryptedSnaid=mtFugfkIjQZwvQduYvOPoJkMUqW8Rkx1t2V4kZtac6o%3D&emailjobid=4646829&emailname=20200520-TBE-F&assetId=AST136084&page=2: https://secure.bonnerandpartners.com/?cid=MKT459805&eid=MKT463356&step=start&plcid=PLC069177&SNAID=SAC0010464081&email=jozef.szlufcik@gmail.com&encryptedSnaid=mtFugfkIjQZwvQduYvOPoJkMUqW8Rkx1t2V4kZtac6o%3D&emailjobid=4646829&emailname=20200520-TBE-F&assetId=AST136084&page=2

Source URL: https://www.stockgumshoe.com/2020/05/microblog-jeff-browns-penny-ipos/


13 responses to “written by reader Jeff Browns “Penny IPO`s””

  1. Zeflik says:

    Two stocks, from previously decoded by Gumshoe community pitching of Jeff Brown, brought me quite good profit. By this I consider him a good analyst worth listening.

  2. dssgateway1 says:

    ANY IDEAS HERE

  3. mclovin says:

    I have not subscribed to the ipo service but have seen the presentation. I’m also in healthcare and familiar with the fda process. I believe IPO 3 is Editas for a few reasons.

    In this presentation, and a few others he’s done for other services, there are slides that appear showing FDA trial data. Trial number can be seen, and in a different video for another service, the actual company was shown. Im sure that was a mistake. But the trial numbers were the same across both.

    Crisper (gene editing) is patented and only used by a handful of companies. In this presentation, in the background, one can see LCA-10 in a slide that is a bit blurry. This is Leber Congenital Amarousis (congenital blindness). By searching publicly-available trial data, the only company that comes up as having a phase 1/2, in vivo, ongoing trial for autosomal dominant LCA is Editas.

    This is it: https://clinicaltrials.gov/ct2/show/NCT03872479

    In other slides, current share price is shown and also fits at 20-30, currently around $27 I believe, as does it’s current market cap.

    In-vivo gene editing, if successful, would be a first-in-class therapy. Editas also has a few other potential gene targets for other conditions.

    I haven’t researched ipo 1 or 2 yet. Interested to hear others’ thoughts.

  4. Pencil says:

    This is my opinion only, based on the (misleadingly annotated) charts in Jeff’s presentation and cross-referencing some of the info he shares with Crunchbase: 1 – KLDO, 2 – DTIL, 3 – EDIT.

  5. Dennis Richardson says:

    How do I but stock? Where in north California do I but it. How do i buy it on the Internet?

  6. Dan l says:

    Got Mr Browns five g play from Travis J and it is up nicely .(akts)

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.